Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valproate + carbamazepine
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous, Rectal
01
Overview
This is a combination therapy of two antiepileptic drugs, valproate (also known as valproic acid or valproate sodium) and carbamazepine. Both are small molecule anticonvulsants used primarily in the management of epilepsy and certain mood disorders. Valproate increases gamma-aminobutyric acid (GABA) levels in the brain by inhibiting GABA transaminase and also affects voltage-gated sodium channels. Carbamazepine acts mainly by blocking voltage-gated sodium channels, stabilizing hyperexcited nerve membranes, inhibiting repetitive neuronal firing, and reducing synaptic propagation of excitatory impulses. The combination may be considered when monotherapy is insufficient for seizure control; however, it carries significant risks due to complex pharmacokinetic interactions that can alter serum concentrations of both drugs and increase toxicity risk[1][4]. This combination should only be used with careful monitoring.
- Other names
- valproic acid + carbamazepinevalproate sodium + carbamazepine
02
Targets
SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)ABAT (4-aminobutyrate aminotransferase)CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on valproate + carbamazepine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valproate + carbamazepine.